These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

860 related articles for article (PubMed ID: 36360302)

  • 1. Antibody-Drug Conjugates for the Treatment of HER2-Positive Breast Cancer.
    Najjar MK; Manore SG; Regua AT; Lo HW
    Genes (Basel); 2022 Nov; 13(11):. PubMed ID: 36360302
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Implementing antibody-drug conjugates (ADCs) in HER2-positive breast cancer: state of the art and future directions.
    Ferraro E; Drago JZ; Modi S
    Breast Cancer Res; 2021 Aug; 23(1):84. PubMed ID: 34380530
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The evolving therapeutic landscape of trastuzumab-drug conjugates: Future perspectives beyond HER2-positive breast cancer.
    von Arx C; De Placido P; Caltavituro A; Di Rienzo R; Buonaiuto R; De Laurentiis M; Arpino G; Puglisi F; Giuliano M; Del Mastro L
    Cancer Treat Rev; 2023 Feb; 113():102500. PubMed ID: 36587473
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ado-trastuzumab emtansine: a HER2-positive targeted antibody-drug conjugate.
    Corrigan PA; Cicci TA; Auten JJ; Lowe DK
    Ann Pharmacother; 2014 Nov; 48(11):1484-93. PubMed ID: 25082874
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel HER2-Targeting Antibody-Drug Conjugates of Trastuzumab Beyond T-DM1 in Breast Cancer: Trastuzumab Deruxtecan(DS-8201a) and (Vic-)Trastuzumab Duocarmazine (SYD985).
    Xu Z; Guo D; Jiang Z; Tong R; Jiang P; Bai L; Chen L; Zhu Y; Guo C; Shi J; Yu D
    Eur J Med Chem; 2019 Dec; 183():111682. PubMed ID: 31563805
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel Anti-HER2 Antibody-Drug Conjugates Versus T-DM1 for HER2-Positive Metastatic Breast Cancer After Tyrosine Kinase Inhibitors Treatment.
    Ji C; Li F; Yuan Y; Zhang H; Bian L; Zhang S; Wang T; Li J; Jiang Z
    Oncologist; 2023 Oct; 28(10):e859-e866. PubMed ID: 37218076
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ado-trastuzumab emtansine (T-DM1): a novel antibody-drug conjugate for the treatment of HER2-positive metastatic breast cancer.
    Baron JM; Boster BL; Barnett CM
    J Oncol Pharm Pract; 2015 Apr; 21(2):132-42. PubMed ID: 24682654
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of trastuzumab emtansine, trastuzumab deruxtecan, and disitamab vedotin in a multiresistant HER2-positive breast cancer lung metastasis model.
    Pourjamal N; Yazdi N; Halme A; Joncour VL; Laakkonen P; Saharinen P; Joensuu H; Barok M
    Clin Exp Metastasis; 2024 Apr; 41(2):91-102. PubMed ID: 38367127
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of Ado-Trastuzumab Emtansine and Fam-Trastuzumab Deruxtecan on Metastatic Breast Cancer Harboring HER2 Amplification and the L755S Mutation.
    Mukohara T; Hosono A; Mimaki S; Nakayama A; Kusuhara S; Funasaka C; Nakao T; Fukasawa Y; Kondoh C; Harano K; Naito Y; Matsubara N; Tsuchihara K; Kuwata T
    Oncologist; 2021 Aug; 26(8):635-639. PubMed ID: 33559918
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Management of patients with HER2-positive metastatic breast cancer after trastuzumab deruxtecan failure.
    Antonarelli G; Corti C; Tarantino P; Salimbeni BT; Zagami P; Marra A; Trapani D; Tolaney S; Cortes J; Curigliano G
    ESMO Open; 2023 Aug; 8(4):101608. PubMed ID: 37467660
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting HER2 in Breast Cancer: Latest Developments on Treatment Sequencing and the Introduction of Biosimilars.
    Tesch ME; Gelmon KA
    Drugs; 2020 Nov; 80(17):1811-1830. PubMed ID: 33021725
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Trastuzumab-DM1: a clinical update of the novel antibody-drug conjugate for HER2-overexpressing breast cancer.
    Barginear MF; John V; Budman DR
    Mol Med; 2013 Jan; 18(1):1473-9. PubMed ID: 23196784
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical perspective: Antibody-drug conjugates for the treatment of HER2-positive breast cancer.
    Najminejad Z; Dehghani F; Mirzaei Y; Mer AH; Saghi SA; Abdolvahab MH; Bagheri N; Meyfour A; Jafari A; Jahandideh S; Gharibi T; Amirkhani Z; Delam H; Mashatan N; Shahsavarani H; Abdollahpour-Alitappeh M
    Mol Ther; 2023 Jul; 31(7):1874-1903. PubMed ID: 36950736
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthesized Anti-HER2 Trastuzumab-MCC-DM1 Conjugate: An Evaluation of Efficacy and Cytotoxicity.
    Shafiee S; Mirzaei R; Salehi M; Jalili N; Taheri A; Farahmand L
    Iran J Immunol; 2023 Sep; 20(3):303-315. PubMed ID: 37434357
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapeutic landscape of advanced HER2-positive breast cancer in 2022.
    Gupta R; Gupta S; Antonios B; Ghimire B; Jindal V; Deol J; Gaikazian S; Huben M; Anderson J; Stender M; Jaiyesimi I
    Med Oncol; 2022 Oct; 39(12):258. PubMed ID: 36224475
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antibody-Drug Conjugates in Breast Cancer: Spotlight on HER2.
    Abelman RO; Medford A; Spring L; Bardia A
    Cancer J; 2022 Nov-Dec 01; 28(6):423-428. PubMed ID: 36383904
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antibody-Drug Conjugates (ADCs) for Personalized Treatment of Solid Tumors: A Review.
    Lambert JM; Morris CQ
    Adv Ther; 2017 May; 34(5):1015-1035. PubMed ID: 28361465
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bystander killing effect of DS-8201a, a novel anti-human epidermal growth factor receptor 2 antibody-drug conjugate, in tumors with human epidermal growth factor receptor 2 heterogeneity.
    Ogitani Y; Hagihara K; Oitate M; Naito H; Agatsuma T
    Cancer Sci; 2016 Jul; 107(7):1039-46. PubMed ID: 27166974
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive breast cancer previously treated with trastuzumab emtansine: a dose-expansion, phase 1 study.
    Tamura K; Tsurutani J; Takahashi S; Iwata H; Krop IE; Redfern C; Sagara Y; Doi T; Park H; Murthy RK; Redman RA; Jikoh T; Lee C; Sugihara M; Shahidi J; Yver A; Modi S
    Lancet Oncol; 2019 Jun; 20(6):816-826. PubMed ID: 31047803
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lung toxicity induced by anti-HER2 antibody - drug conjugates for breast cancer.
    Chai M; Li L; Wu H; Liu Y; Yi Z; Yu H
    Crit Rev Oncol Hematol; 2024 Mar; 195():104274. PubMed ID: 38295890
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 43.